Original Article
A Comparison of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with the Antiphospholipid Antibody Syndrome
N Engl J Med 2003; 349:1133-1138September 18, 2003
- Abstract
Background
Many patients with the antiphospholipid antibody syndrome and recurrent thrombosis receive doses of warfarin adjusted to achieve an international normalized ratio (INR) of more than 3.0. However, there are no prospective data to support this approach to thromboprophylaxis.
Methods
We performed a randomized, double-blind trial in which patients with antiphospholipid antibodies and previous thrombosis were assigned to receive enough warfarin to achieve an INR of 2.0 to 3.0 (moderate intensity) or 3.1 to 4.0 (high intensity). Our objective was to show that high-intensity warfarin was more effective in preventing thrombosis than moderate-intensity warfarin.
Results
A total of 114 patients were enrolled in the study and followed for a mean of 2.7 years. Recurrent thrombosis occurred in 6 of 56 patients (10.7 percent) assigned to receive high-intensity warfarin and in 2 of 58 patients (3.4 percent) assigned to receive moderate-intensity warfarin (hazard ratio for the high-intensity group, 3.1; 95 percent confidence interval, 0.6 to 15.0). Major bleeding occurred in three patients assigned to receive high-intensity warfarin and four patients assigned to receive moderate-intensity warfarin (hazard ratio, 1.0; 95 percent confidence interval, 0.2 to 4.8).
Conclusions
High-intensity warfarin was not superior to moderate-intensity warfarin for thromboprophylaxis in patients with antiphospholipid antibodies and previous thrombosis. The low rate of recurrent thrombosis among patients in whom the target INR was 2.0 to 3.0 suggests that moderate-intensity warfarin is appropriate for patients with the antiphospholipid antibody syndrome.
Media in This Article
Figure 1
Time to First Recurrent Thrombosis for All Patients Enrolled in the Study.Table 1
Base-Line Characteristics of the Patients.Article Activity
- Article
Antiphospholipid antibodies, which include anticardiolipin antibodies and lupus anticoagulant, are associated with both arterial and venous thrombosis.1 After a first episode of thrombosis, patients with antiphospholipid antibodies have a higher risk of recurrent thrombosis than do patients without antiphospholipid antibodies.1 Retrospective studies suggest that patients with antiphospholipid antibodies have a high risk of recurrent thrombosis while receiving moderate-intensity warfarin (target international normalized ratio [INR], 2.0 to 3.0) and that this risk is lower with a higher intensity of anticoagulant therapy (target INR, 3.1 to 4.5).2-4 However, these results must be interpreted with caution, because the studies were retrospective case series, recurrent thrombosis was not confirmed by independent adjudication, and the INR at the time of the thrombotic events was uncertain. Furthermore, the patients in these studies attended special clinics where the staff had an interest in the management of complex problems in patients with antiphospholipid antibodies and who were therefore likely to be in a selected subgroup of patients at high risk for recurrent thrombosis.
To our knowledge, there have been no randomized trials of the efficacy and safety of high-intensity versus moderate-intensity warfarin therapy in patients with the antiphospholipid antibody syndrome. Because increasing the target INR from a range of 2.0 to 3.0 to a range of 3.1 to 4.0 is likely to be associated with a doubling of the risk of major hemorrhage, it is important to know whether the higher-intensity treatment is more effective.5,6
To determine whether high-intensity warfarin therapy is required in patients with antiphospholipid antibodies and a previous episode of thrombosis, we undertook a randomized, double-blind trial to compare long-term warfarin therapy targeted to an INR of 2.0 to 3.0 with therapy targeted to an INR of 3.1 to 4.0. Our hypothesis was that high-intensity warfarin would be more effective than moderate-intensity therapy.
Methods
Study Patients
Patients were recruited from tertiary care rheumatology and thromboembolism clinics. They were eligible if they had had an objectively confirmed arterial or venous thrombosis and a positive test for antiphospholipid antibodies on two occasions at least three months apart. Testing for antiphospholipid antibodies was carried out in local clinical laboratories. Acceptable candidates included those whose tests showed the presence of lupus anticoagulant, as defined by the International Society on Thrombosis and Haemostasis,7 a moderate or high titer of IgG anticardiolipin antibody, or both. Patients who had only IgM anticardiolipin antibodies were not eligible for the study. Patients were also excluded if they had a clinically significant bleeding diathesis (e.g., refractory thrombocytopenia with a platelet count of less than 50,000 per cubic millimeter); a history of intracranial hemorrhage, stroke, or gastrointestinal bleeding within the previous three months; a contraindication to warfarin (e.g., allergy); a history of objectively confirmed recurrent thrombosis while receiving warfarin targeted to an INR of 2.0 or greater; pregnancy or a planned pregnancy during the study period; or a geographic location that would preclude follow-up.
Randomization and Treatment
The study was approved by the local institutional review board of each of the 13 participating centers, and all patients provided written informed consent before enrollment. Patients were randomized by means of telephone calls to the study coordinating center. Patients were stratified according to the presence or absence of previous arterial thromboembolism and according to the clinical center. The randomization sequence was generated with the use of a random-number table and was performed in blocks of two, four, or six patients.
To minimize bias, we tried to ensure that patients, treating physicians, and other study personnel and adjudicators were unaware of the treatment assignments. Hence, INR results were forwarded to the central warfarin monitors. The warfarin monitors instructed the clinical centers about the warfarin dosage and when to perform INR testing. Thus, physicians, nurse coordinators, and patients remained unaware of both the assigned intensity of warfarin and the INR achieved. To reduce the risk of unblinding, clinicians were discouraged from performing INR assessments when patients presented with suspected recurrent episodes of thrombosis until these were confirmed by testing.
After analysis of the trial data, unscheduled INR measurements that had been performed by the clinical centers during an episode of recurrent thrombosis were obtained from the patient's clinical record. If the INR had not been measured on the day of the episode, the reported INR value was the value at the last scheduled visit before diagnosis of the episode. Similar strategies for masking warfarin therapy have been used successfully in previous clinical trials.8,9
Follow-up and Outcomes
Follow-up data were obtained in the clinic or by telephone at three-month intervals. Patients were seen in the clinic at least twice yearly and were asked about symptoms and signs of recurrent thrombosis. Patients were instructed to go to the local emergency department or to contact a study physician if symptoms or signs suggestive of recurrent thrombosis or major bleeding developed. Objective diagnostic testing was performed if a thrombotic event was suspected. If the test results were positive, they were forwarded to the coordinating center.
The primary outcome measure with respect to efficacy was an episode of recurrent thrombosis (a stroke or transient ischemic attack, myocardial infarction, peripheral arterial thrombosis, cerebral-vein thrombosis, deep-vein thrombosis, or pulmonary embolism) that was confirmed by adjudication. The primary outcome measure with respect to safety was bleeding.
All thrombotic and bleeding events were adjudicated by a blinded central adjudication committee of two experts. The criteria for and classification of these events were prespecified.
Statistical Analysis
Estimation of the required sample size was based on two assumptions: first, that the risk of recurrent thrombosis would be approximately 15 percent per year in the group receiving moderate-intensity warfarin therapy and 2.5 percent per year in the group receiving high-intensity warfarin therapy2; and, second, that the average duration of follow-up would be approximately three years. With the use of a two-sided alpha error of 5 percent and a power of 80 percent, a total of 76 patients (38 per group) would be required to demonstrate that high-intensity warfarin was more effective than moderate-intensity warfarin. To protect against an underpowered comparison owing to either loss to follow-up or overestimation of the efficacy of high-intensity therapy, the originally planned sample size was increased to a total of 90 patients.
The primary analysis was based on the intention-to-treat principle. The time to a first recurrent thrombotic event in the two treatment groups was compared with the use of the log-rank test. A similar analysis was planned for bleeding events. Hazard ratios for recurrent thrombosis were calculated with the use of the Cox proportional-hazards model.
As originally designed, the study called for a minimum of two years of follow-up for the 90th and final patient enrolled. Immediately before enrollment of the 90th patient, the steering committee reviewed the total number of thrombotic events that had been reported to the coordinating center. While remaining unaware of the treatment assignments, the steering committee noted that the overall rate of thrombosis was much lower than expected. To increase both recruitment and the number of patient-years of follow-up without prolonging the study, the steering committee extended enrollment for an additional 18 months and reduced the duration of follow-up for the final patient enrolled to six months.
Results
Of 325 patients screened, 207 met the criteria for inclusion in the study, and of these, 42 were excluded. The reasons most frequently given for exclusion were pregnancy or planned pregnancy (in nine patients), a high risk of hemorrhage (eight), or previous failure of moderate-intensity warfarin (six). Fifty-one patients declined participation. Thus, a total of 114 patients were enrolled at 13 clinical centers between February 1998 and May 2001. The patients' characteristics were similar in the two groups except that there was a higher proportion of women in the moderate-intensity group (Table 1Table 1
Base-Line Characteristics of the Patients.). The average duration of follow-up was 2.7 years in the moderate-intensity group and 2.6 years in the high-intensity group.Eight patients (7.0 percent) from seven clinical centers had recurrent thrombosis: 6 (10.7 percent) of the 56 patients assigned to high-intensity warfarin therapy and 2 (3.4 percent) of the 58 patients assigned to receive moderate-intensity warfarin therapy (hazard ratio, 3.1; 95 percent confidence interval, 0.6 to 15.0; P=0.15) (Figure 1Figure 1
Time to First Recurrent Thrombosis for All Patients Enrolled in the Study. and Table 2Table 2
Outcomes and Duration of Follow-up in the High-Intensity and Moderate-Intensity Warfarin Groups, According to Subgroup.). Of the two recurrences in the moderate-intensity group, one was a myocardial infarction in a patient with both previous myocardial infarction and previous deep-vein thrombosis, and the other was a deep-vein thrombosis in a patient with previous deep-vein thrombosis. The INR values in these two patients were 1.6 and 2.8, respectively.The six recurrences in the high-intensity warfarin group included a deep-vein thrombosis in a patient with both previous peripheral arterial thrombosis and previous deep-vein thrombosis, a stroke in a patient with a previous deep-vein thrombosis, a deep-vein thrombosis in a patient with previous stroke, a pulmonary embolism in a patient with previous pulmonary embolism, a myocardial infarction in a patient with previous myocardial infarction, and a deep-vein thrombosis in a patient with previous pulmonary embolism. Five of these six patients continued to receive high-intensity warfarin; their INR values were 3.1, 1.0, 0.9, 1.9, and 3.9, respectively. The sixth patient had discontinued the warfarin 137 days before the recurrent event.
Thirteen patients treated with moderate-intensity warfarin discontinued the drug prematurely. Of these, five stopped at the time of a suspected thrombotic event (confirmed on adjudication in two patients), one stopped because of a major hemorrhage, and seven withdrew consent. Of the seven who withdrew consent, two could not be followed to the end of the study, and data on these patients were censored 69 and 414 days after enrollment.
Twenty-one patients treated with high-intensity warfarin discontinued the drug prematurely. Of these, 5 stopped at the time of a suspected thrombotic event (confirmed on adjudication), 3 stopped because of a major hemorrhage, 1 became pregnant, clinically significant thrombocytopenia developed in 1, and 11 withdrew consent. Of these 21 patients, 1 had a confirmed deep-vein thrombosis three months later. Of the 11 patients who withdrew consent, 4 could not be followed to the end of the study, and data on these patients were censored at 60, 148, 657, and 726 days.
The average INR values in the moderate- and high-intensity warfarin groups were 2.3 and 3.3, respectively. In the moderate-intensity group, the INR was above the target range 11 percent of the time, within the range 71 percent of the time, and below it 19 percent of the time. In the high-intensity group, the corresponding figures were 17, 40, and 43 percent. Eighty-six percent of the time that the INR in patients assigned to high-intensity warfarin was “subtherapeutic,” it was between 2.0 and 3.1.
Major bleeding occurred in four patients assigned to moderate-intensity warfarin and in three assigned to high-intensity warfarin (Table 2). The annual risk of major bleeding was 2.2 percent with moderate-intensity warfarin and 3.6 percent with high-intensity warfarin. Eleven patients (19 percent) in the moderate-intensity group and 14 patients (25 percent) in the high-intensity group had at least one episode of bleeding (Table 2). No patient died during the study.
Multivariable analyses with the use of the Cox model did not reveal any statistically significant confounding due to the base-line characteristics or stratification factors for any of the study outcomes. The small number of recurrent events precluded a meaningful analysis of the relation between base-line prognostic factors and the risk of recurrent thrombosis.
Discussion
In this study, we found that high-intensity warfarin therapy is not more effective than moderate-intensity warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid antibodies. Our results also showed that the absolute risk of recurrent thrombosis was low if warfarin therapy was targeted to an INR of 2.0 to 3.0.
The findings of this study are different from those of previous studies in which patients with the antiphospholipid antibody syndrome had a high risk of recurrent thrombosis when treated with moderate-intensity warfarin.2,3 There are several reasons for these differences. Most important, the previous studies were retrospective, and, as a consequence, neither the rates of recurrent thrombosis nor the intensity of anticoagulant therapy received at the time of the recurrent events could be accurately determined. In contrast, we enrolled patients prospectively, evaluated recurrent events objectively, and obtained accurate data on the intensity of anticoagulant therapy for all patients. In addition, previous studies enrolled patients at a few highly specialized clinics that had an interest in managing complex problems related to antiphospholipid antibodies.
Our results are likely to be valid and generalizable, because the study was randomized and double-blinded, central adjudication was used, and patients were enrolled at 13 clinical centers. Positive results of two consecutive antiphospholipid-antibody tests performed three months apart were required for enrollment in order to reduce the likelihood that patients whose test results were transiently positive, and therefore potentially less clinically important, would be included.10 Base-line variables were evenly distributed between the two groups, with the exception that the moderate-intensity group had a higher proportion of women. This imbalance occurred as a result of chance and did not confound the results of the study.
This study has several limitations. Because we required all patients to have two positive antiphospholipid-antibody tests three months apart, we did not examine the effectiveness of warfarin in the initial three months after a first episode of thrombosis. We excluded patients with a high risk of bleeding and those who had had a thrombosis while taking warfarin, and thus we cannot comment on how warfarin therapy for such patients should be managed. Because only 14 patients (8 of whom were assigned to high-intensity warfarin) were also treated with aspirin, it is not possible to draw meaningful conclusions about the concomitant use of aspirin and its influence on the frequency of recurrent thrombosis or bleeding. In addition, the rate of recurrent thrombosis might have been lower if the INRs in patients assigned to high-intensity warfarin had been in the desired range during a greater portion of the study period. However, this failing is unlikely to have had a major influence on the results, given that only one of the recurrent thrombotic episodes in the high-intensity warfarin group occurred in a patient who had prematurely discontinued the assigned treatment. Furthermore, the average INR value was fully 1 point higher in the high-intensity group than in the moderate-intensity group. Finally, because the rate of recurrent thrombosis in the moderate-intensity group was very low, it is unlikely that strict maintenance of an INR greater than 3.0 in the high-intensity group would have improved this result.
Supported by a grant from the Canadian Institutes for Health Research (MCT 14390). Dr. Crowther holds a Research Scholarship from the Canadian Institutes for Health Research. Dr. Ginsberg is a Career Investigator of the Heart and Stroke Foundation of Ontario. Drs. Douketis and Kearon each hold Research Scholarships from the Heart and Stroke Foundation of Canada. Dr. Kovacs is an Internal Scholar of the Department of Medicine at the University of Western Ontario, Canada. Dr. Clarke is a Career Investigator of the Canadian Institutes for Health Research. Dr. Fortin is a Scientist of the Arthritis Society/Canadian Institutes for Health Research and is supported in part by the Arthritis Center of Excellence of the University of Toronto.
DuPont Pharma provided the warfarin used in the study.
Source Information
From the Departments of Medicine (M.A.C., J.S.G., J. Denburg, J.H., J. Douketis, C.K.) and Clinical Epidemiology and Biostatistics (J.J., L.C., W.Y., M.G.), McMaster University, Hamilton, Ont.; the Department of Medicine (C.L., P.F., W.G.) and the Undergraduate Medical Program (S.W.), University of Toronto, Toronto; the Department of Medicine, Dalhousie University, Halifax, N.S. (D.A.); the Department of Medicine, McGill University, Montreal (A.C.); the Department of Medicine, University of Ottawa, Ottawa, Ont. (M.F.); and the Department of Medicine, University of Western Ontario, London, Ont. (M.J.K.) — all in Canada; and the Department of Medicine, Northwestern University, Chicago (D.G.).
Address reprint requests to Dr. Crowther at St. Joseph's Hospital, Rm. L208, 50 Charlton Ave. E., Hamilton, ON L8N 4A6, Canada, or at crowthrm@mcmaster.ca.
- References
References
1
Crowther MA, Ginsberg JS. Antiphospholipid antibody syndrome. In: Goldhaber SZ, Ridker PM, eds. Thrombosis and thromboembolism. Vol. 44 of Fundamental and clinical cardiology. New York: Marcel Dekker, 2002:49-66.
2
Khamashta MA ,Cuadrado MJ ,Mujic F ,Taub NA ,Hunt BJ ,Hughes GRV . The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332:993-997
Full Text | Web of Science | Medline3
Rosove MH ,Brewer PM . Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-308
Web of Science | Medline4
Ruiz-Irastorza G ,Khamashta MA ,Hunt BJ ,Escudero A ,Cuadrado MJ ,Hughes GR . Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002;162:1164-1169
CrossRef | Web of Science | Medline5
Palareti G ,Leali N ,Coccheri S , et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT): Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-428
CrossRef | Web of Science | Medline6
Oden A ,Fahlen M . Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002;325:1073-1075
CrossRef | Web of Science | Medline7
Brandt JT ,Barna LK ,Triplett DA . Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. Thromb Haemost 1995;74:1597-1603
Web of Science | Medline8
Crowther MA ,Clase CM ,Margetts PJ , et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol 2002;13:2331-2337
CrossRef | Web of Science | Medline9
Kearon C ,Gent M ,Hirsh J , et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999;340:901-907[Erratum, N Engl J Med 1999;341:298.]
Full Text | Web of Science | Medline10
Wilson WA ,Gharavi AE ,Koike T , et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999;42:1309-1311
CrossRef | Web of Science | Medline
- Citing Articles (183)
Citing Articles
1
David Keeling, Ian Mackie, Gary W. Moore, Ian A. Greer, Michael Greaves, . (2012) Guidelines on the investigation and management of antiphospholipid syndrome. British Journal of Haematologyn/a-n/a
CrossRef2
A. Delluc, F. Le Ven, D. Mottier, G. Le Gal. (2012) Épidémiologie et facteurs de risque de la maladie veineuse thromboembolique. Revue des Maladies Respiratoires
CrossRef3
S. Middeldorp. (2011) Is Thrombophilia Testing Useful?. Hematology 2011:1, 150-155
CrossRef4
Kessarin Panichpisal, Eduard Rozner, Steven R. Levine. (2011) The Management of Stroke in Antiphospholipid Syndrome. Current Rheumatology Reports
CrossRef5
Bharath M. Akkara Veetil, Tim Bongartz. (2011) Perioperative care for patients with rheumatic diseases. Nature Reviews Rheumatology
CrossRef6
Naoyuki Nishimura, Hironori Yamamoto, Tomonori Yano, Yoshikazu Hayashi, Hiroyuki Sato, Yoshimasa Miura, Hakuei Shinhata, Keijiro Sunada, Kentaro Sugano. (2011) Balloon dilation when using double-balloon enteroscopy for small-bowel strictures associated with ischemic enteritis. Gastrointestinal Endoscopy 74:5, 1157-1161
CrossRef7
F. Couturaud. (2011) Durée optimale du traitement anticoagulant au décours d’une embolie pulmonaire. Revue des Maladies Respiratoires
CrossRef8
Vittorio Pengo, Guillermo Ruiz-Irastorza, Gentian Denas, Laura Andreoli, Munther Khamashta, Angela Tincani. (2011) High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: ‘PROS’ and ‘CONS’. Autoimmunity Reviews
CrossRef9
Tina Scoble, Sonali Wijetilleka, Munther A. Khamashta. (2011) Management of refractory anti-phospholipid syndrome. Autoimmunity Reviews 10:11, 669-673
CrossRef10
Hayan Moualla, David Garcia. (2011) Vitamin K Antagonists – Current Concepts and Challenges. Thrombosis Research 128:3, 210-215
CrossRef11
Mariana Postal, Lilian T.L. Costallat, Simone Appenzeller. (2011) Neuropsychiatric Manifestations in Systemic Lupus Erythematosus. CNS Drugs 25:9, 721-736
CrossRef12
Allison Burnett, Jason Cohen, David A. Garcia. 2011. Hemorrhagic Complications of Anticoagulants in Hospitalized Patients. , 291-330.
CrossRef13
David Keeling, Trevor Baglin, Campbell Tait, Henry Watson, David Perry, Caroline Baglin, Steve Kitchen, Michael Makris, . (2011) Guidelines on oral anticoagulation with warfarin - fourth edition. British Journal of Haematology 154:3, 311-324
CrossRef14
A. Tripodi, P. G. de Groot, V. Pengo. (2011) Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. Journal of Internal Medicine 270:2, 110-122
CrossRef15
Guillaume Geri, Patrice Cacoub. (2011) Atteinte cardiaque au cours du syndrome des antiphospholipides. La Presse Médicale 40:7-8, 758-764
CrossRef16
Ombeline Fagniez, Gérard Tertian, Marie Dreyfus, Denis Ducreux, David Adams, Christian Denier. (2011) Hematological disorders related cerebral infarctions are mostly multifocal. Journal of the Neurological Sciences 304:1-2, 87-92
CrossRef17
Andrea Lee, Mark Crowther. (2011) Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure. Journal of Thrombosis and Thrombolysis 31:3, 249-258
CrossRef18
Michael B. Streiff. (2011) Anticoagulation in the management of venous thromboembolism in the cancer patient. Journal of Thrombosis and Thrombolysis 31:3, 282-294
CrossRef19
J. Rosencher, T. Mirault, I. Martinez, T. Zhu, E. Messas, J. Emmerich. (2011) Facteurs de risque de récidive de la maladie thromboembolique veineuse. Revue des Maladies Respiratoires 28:4, 453-462
CrossRef20
Vittorio Pengo. (2011) APS – controversies in diagnosis and management, critical overview of current guidelines. Thrombosis Research 127, S51-S52
CrossRef21
Bas Laat, Philip G. Groot. (2011) Autoantibodies Directed Against Domain I of Beta2-Glycoprotein I. Current Rheumatology Reports 13:1, 70-76
CrossRef22
Mike Greaves. (2011) Antiphospholipid syndrome: Unusual clinical presentations. Thrombosis Research 127, S47-S50
CrossRef23
Benjamín Rubio-Jurado, Paulina Iñiguez-Franco, Pedro A. Reyes, Gustavo Robles, Mario Salazar-Páramo, Guadalupe Zavala-Cerna, Carlos Riebeling, Arnulfo Nava. (2011) The Clinical Significance of Coagulation and the Inflammatory Response in Autoimmunity. Clinical Reviews in Allergy & Immunology
CrossRef24
O. Meyer. (2011) S
ndrome antifosfol
CrossRef25
Roman M. Sniecinski, Marcie J. Hursting, Michael J. Paidas, Jerrold H. Levy. (2011) Etiology and Assessment of Hypercoagulability with Lessons from Heparin-Induced Thrombocytopenia. Anesthesia & Analgesia 112:1, 46-58
CrossRef26
Tadej Avčin, Kathleen M. O’Neil. 2011. ANTIPHOSPHOLIPID SYNDROME. , 344-360.
CrossRef27
Bruce M. Coull, Kendra Drake. 2011. Coagulation Abnormalities in Stroke. , 772-789.
CrossRef28
Scott E. Kasner, Brett L. Cucchiara. 2011. Treatment of “Other” Stroke Etiologies. , 1084-1105.
CrossRef29
John G. Hanly. 2011. The Nervous System and Lupus. , 727-746.
CrossRef30
Gerard Espinosa, Ricard Cervera. 2011. Treatment of Antiphospholipid Syndrome. , 1027-1042.
CrossRef31
Fiona Ryan, Susan O'Shea, Stephen Byrne. (2010) The ‘carry-over’ effects of patient self-testing: Positive effects on usual care management by an anticoagulation management service. Thrombosis Research 126:5, e345-e348
CrossRef32
Guillermo Ruiz-Irastorza, Mark Crowther, Ware Branch, Munther A Khamashta. (2010) Antiphospholipid syndrome. The Lancet 376:9751, 1498-1509
CrossRef33
Tamihiro Kawakami, Yoshinao Soma. (2010) Use of warfarin therapy at a target international normalized ratio of 3.0 for cutaneous polyarteritis nodosa. Journal of the American Academy of Dermatology 63:4, 602-606
CrossRef34
T. Flint Porter, D. Ware Branch. 2010. Systemic Lupus Erythematosus and Antiphospholipid Syndrome. , 475-486.
CrossRef35
H. James Ford, Robert A.S. Roubey. (2010) Pulmonary Manifestations of the Antiphospholipid Antibody Syndrome. Clinics in Chest Medicine 31:3, 537-545
CrossRef36
Benjamin Sussman, B. Brent Simmons. (2010) Antiphospholipid antibody syndrome causing acute myocardial infarction in a young adult. Osteopathic Family Physician 2:5, 139-143
CrossRef37
Marco P. Donadini, Mark Crowther. (2010) Antiphospholipid Syndrome: A Challenging Hypercoagulable State with Systemic Manifestations. Hematology/Oncology Clinics of North America 24:4, 669-676
CrossRef38
Lonneke ML de Lau, Frank WG Leebeek, Moniek PM de Maat, Peter J Koudstaal, Diederik WJ Dippel. (2010) Screening for coagulation disorders in patients with ischemic stroke. Expert Review of Neurotherapeutics 10:8, 1321-1329
CrossRef39
Megan Alcauskas, Steven R. Levine. 2010. Cerebrovascular Disease Associated with Antiphospholipid Antibodies. , 59-60.
CrossRef40
Henry G. Watson, Beverley J. Robertson. 2010. Antiphospholipid Syndrome. , 177-184.
CrossRef41
Gerard Espinosa, Ricard Cervera. (2010) Management of the antiphospholipid syndrome. Autoimmunity Highlights 1:1, 15-22
CrossRef42
A. Tufano, A. Guida, M.N.D. Di Minno, A.M. De Gregorio, A.M. Cerbone, Giovanni Di Minno. (2010) Cardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention. Nutrition, Metabolism and Cardiovascular Diseases 20:4, 217-223
CrossRef43
P. MISMETTI, S. LAPORTE. (2010) New oral antithrombotics: a need for laboratory monitoring. For. Journal of Thrombosis and Haemostasis 8:4, 621-626
CrossRef44
Ali A Mehdi, Imad Uthman, Munther Khamashta. (2010) Treatment of antiphospholipid antibody syndrome. International Journal of Clinical Rheumatology 5:2, 241-254
CrossRef45
Carlos E. M. Rodrigues, Jozélio F. Carvalho, Yehuda Shoenfeld. (2010) Neurological manifestations of antiphospholipid syndrome. European Journal of Clinical Investigation 40:4, 350-359
CrossRef46
Michael Makris, Joost J. Veen, Rhona Maclean. (2010) Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient. Journal of Thrombosis and Thrombolysis 29:2, 171-181
CrossRef47
V. PENGO, A. RUFFATTI, C. LEGNANI, P. GRESELE, D. BARCELLONA, N. ERBA, S. TESTA, F. MARONGIU, E. BISON, G. DENAS, A. BANZATO, S. PADAYATTIL JOSE, S. ILICETO. (2010) Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. Journal of Thrombosis and Haemostasis 8:2, 237-242
CrossRef48
Francesco Dentali, Mark Crowther. (2010) Antiphospholipid antibodies in critical illness. Critical Care Medicine 38, S51-S56
CrossRef49
Mark Crowther, Mark A. Crowther. (2010) Intensity of Warfarin Coagulation in the Antiphospholipid Syndrome. Current Rheumatology Reports 12:1, 64-69
CrossRef50
Yukari YOSHIDA, Riho ISHIKAWA, Yoshinao MURO. (2010) A Case of Perniosis with Antiphospholipid Antibody. Nishi Nihon Hifuka 72:3, 201-203
CrossRef51
Doruk Erkan, Robert A.S. Roubey. 2010. Management of the Antiphospholipid Syndrome. , 124-133.
CrossRef52
Ricard Cervera. (2010) Therapeutic strategies in antiphospholipid syndrome. Reumatolog ía Cl ínica (English Edition) 6:1, 37-42
CrossRef53
Paula I Burgos, Graciela S Alarcón. (2009) Thrombosis in systemic lupus erythematosus: risk and protection. Expert Review of Cardiovascular Therapy 7:12, 1541-1549
CrossRef54
Dolores Puente, Gonzalo Pombo, Ricardo Forastiero. (2009) Current management of antiphospholipid syndrome-related thrombosis. Expert Review of Cardiovascular Therapy 7:12, 1551-1558
CrossRef55
Alan M Seif, Yong Hwang, Silvia S Pierangeli. (2009) Management of the antiphospholipid syndrome: new approaches. International Journal of Clinical Rheumatology 4:5, 533-549
CrossRef56
Angela Tincani, Tamara Ziglioli, Laura Andreoli, Pierluigi Meroni. (2009) Update on antiphospholipid antibodies: clinical significance. International Journal of Clinical Rheumatology 4:5, 551-560
CrossRef57
B. Giannakopoulos, S. A. Krilis. (2009) How I treat the antiphospholipid syndrome. Blood 114:10, 2020-2030
CrossRef58
Diane George, Doruk Erkan. (2009) Antiphospholipid Syndrome. Progress in Cardiovascular Diseases 52:2, 115-125
CrossRef59
Guillermo Ruiz-Irastorza, Agustin Martinez-Berriotxoa, M.V. Egurbide. (2009) Síndrome antifosfolipídico en el siglo xxi. Medicina Clínica 133:10, 390-396
CrossRef60
Praveen Jajoria, Vijaya Murthy, Elizabeth Papalardo, Zurina Romay-Penabad, Caroline Gleason, Silvia S. Pierangeli. (2009) Statins for the Treatment of Antiphospholipid Syndrome?. Annals of the New York Academy of Sciences 1173:1, 736-745
CrossRef61
Hong-Jian Shi, You-Hua Huang, Tao Shen, Qiang Xu. (2009) Percutaneous mechanical thrombectomy combined with catheter-directed thrombolysis in the treatment of symptomatic lower extremity deep venous thrombosis. European Journal of Radiology 71:2, 350-355
CrossRef62
Ian Giles, Anisur Rahman. (2009) How to manage patients with systemic lupus erythematosus who are also antiphospholipid antibody positive. Best Practice & Research Clinical Rheumatology 23:4, 525-537
CrossRef63
Charles Eby. (2009) Antiphospholipid Syndrome Review. Clinics in Laboratory Medicine 29:2, 305-319
CrossRef64
Eyal Zifman, Pnina Rotman-Pikielny, Tatiana Berlin, Yair Levy. (2009) Insertion of Inferior Vena Cava Filters in Patients with the Antiphospholipid Syndrome. Seminars in Arthritis and Rheumatism 38:6, 472-477
CrossRef65
Richard H. White, Robert C. Gosselin. (2009) Testing for Thrombophilia: Pitfalls, Limitations, and Marginal Impact on Treatment Duration Recommendations. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:3, 303-313
CrossRef66
Benjamin M. Greenberg. (2009) The Neurologic Manifestations of Systemic Lupus Erythematosus. The Neurologist 15:3, 115-121
CrossRef67
Pat Foy, Stephan Moll. (2009) Thrombophilia: 2009 update. Current Treatment Options in Cardiovascular Medicine 11:2, 114-128
CrossRef68
Doruk Erkan, Michael D Lockshin. (2009) New approaches for managing antiphospholipid syndrome. Nature Clinical Practice Rheumatology 5:3, 160-170
CrossRef69
Patricia Weyland. (2009) Warfarin therapy management. The Nurse Practitioner 34:3, 22-28
CrossRef70
David D’Cruz. (2009) Renal manifestations of the antiphospholipid syndrome. Current Rheumatology Reports 11:1, 52-60
CrossRef71
W. Lim. (2009) Antiphospholipid antibody syndrome. Hematology 2009:1, 233-239
CrossRef72
Mike Greaves. (2009) Pathogenesis and management of antiphospholipid syndrome. Thrombosis Research 123, S4-S9
CrossRef73
M BRIONES. 2009. Antiphospholipid Antibody Syndrome. , 515-517.
CrossRef74
Saskia Middeldorp, Astrid van Hylckama Vlieg. (2008) Does thrombophilia testing help in the clinical management of patients?. British Journal of Haematology 143:3, 321-335
CrossRef75
Stuart Weiss, Joseph B. Nyzio, Douglas Cines, John Detre, Bonnie L. Milas, Navneet Narula, Thomas F. Floyd. (2008) Antiphospholipid Syndrome: Intraoperative and Postoperative Anticoagulation in Cardiac Surgery. Journal of Cardiothoracic and Vascular Anesthesia 22:5, 735-739
CrossRef76
Jean-Louis Pasquali, Vincent Poindron, Anne-Sophie Korganow, Thierry Martin. (2008) The antiphospholipid syndrome. Best Practice & Research Clinical Rheumatology 22:5, 831-845
CrossRef77
B. Giannakopoulos, F. Passam, Y. Ioannou, S. A. Krilis. (2008) How we diagnose the antiphospholipid syndrome. Blood 113:5, 985-994
CrossRef78
D. Wahl, C. Perret-Guillaume, J.-C. Piette. (2008) Traitement des complications thrombotiques du syndrome des anticorps antiphospholipides : éclairages des essais thérapeutiques récents et zones d’ombre. La Revue de Médecine Interne 29:9, 731-734
CrossRef79
J. H. Rand, X.-X. Wu, A. S. Quinn, P. P. Chen, J. J. Hathcock, D. J. Taatjes. (2008) Hydroxychloroquine directly reduces the binding of antiphospholipid antibody- 2-glycoprotein I complexes to phospholipid bilayers. Blood 112:5, 1687-1695
CrossRef80
J. P. PATEL, B. J. HUNT. (2008) Where do we go now with low molecular weight heparin use in obstetric care?. Journal of Thrombosis and Haemostasis 6:9, 1461-1467
CrossRef81
D. WAHL, O. THIEBAUGEORGES, V. REGNAULT, A. DALLOUL, T. LECOMPTE. (2008) Pursuing the debate on the serologic criteria that define the antiphospholipid syndrome. Journal of Thrombosis and Haemostasis 6:8, 1433-1435
CrossRef82
Lannery S. Lauvao, Kaoru R. Goshima, Luis R. Leon, Paul E. Nolan, John D. Hughes. (2008) Superficial femoral artery thrombosis as a cause for distal embolism in primary antiphospholipid syndrome. Journal of Vascular Surgery 48:2, 472-477
CrossRef83
N. Belkahla, N. Maamouri, H. Ouerghi, I. Cheikh, S. Ben Hamida, H. Bouzid, A.B. Ammar. (2008) Thrombose portocave extensive révélant un syndrome primaire des anticorps antiphospholipides : à propos d’un cas. La Revue de Médecine Interne 29:6, 504-507
CrossRef84
Jorge L. Musuruana, Javier A. Cavallasca. (2008) Polyarteritis Nodosa Complicated by Antiphospholipid Syndrome. Southern Medical Journal 101:4, 419-421
CrossRef85
David Tanne, Aviva Katzav, Orit Beilin, Nikolaos C. Grigoriadis, Miri Blank, Chaim G. Pick, Philipp von Landenberg, Yehuda Shoenfeld, Joab Chapman. (2008) Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiology of Disease 30:1, 56-64
CrossRef86
Yen-Chu Huang, Rong-Kuo Lyu, Sien-Tsong Chen, Yi-Chuan Chu, Yih-Ru Wu. (2008) Parkinsonism in a patient with antiphospholipid syndrome — Case report and literature review. Journal of the Neurological Sciences 267:1-2, 166-169
CrossRef87
J. Criado-García, R.A. Fernández-Puebla, L. López Jiménez, F. Velasco, M. Santamaría, A. Blanco-Molina. (2008) Retirada de la anticoagulación en el síndrome antifosfolípido primario cuando se negativizan los anticuerpos anticardiolipina. Revista Clínica Española 208:3, 135-137
CrossRef88
Silvia S Pierangeli. (2008) Novel therapies for the antiphospholipid syndrome. Expert Review of Clinical Immunology 4:2, 193-203
CrossRef89
Dolores Puente, Ricardo Forastiero. (2008) New insights into the management of antiphospholipid syndrome-related thrombosis. Future Rheumatology 3:1, 85-93
CrossRef90
Rima M. Dafer, José Biller. (2008) Antiphospholipid Syndrome: Role of Antiphospholipid Antibodies in Neurology. Hematology/Oncology Clinics of North America 22:1, 95-105
CrossRef91
Eyal Muscal, Robin L. Brey. (2008) Neurologic manifestations of the antiphospholipid syndrome: Integrating molecular and clinical lessons. Current Rheumatology Reports 10:1, 67-73
CrossRef92
William F. Baker, Rodger L. Bick, Jawed Fareed. (2008) Controversies and Unresolved Issues in Antiphospholipid Syndrome Pathogenesis and Management. Hematology/Oncology Clinics of North America 22:1, 155-174
CrossRef93
Doruk Erkan, Michael D. Lockshin. 2008. Antiphospholipid syndrome. , 909-917.
CrossRef94
Junichi KABURAKI. (2008) Clinical features and treatments of antiphospholipid syndrome. Japanese Journal of Clinical Immunology 31:3, 152-158
CrossRef95
N. A. Goldenberg. (2008) Thrombophilia States and Markers of Coagulation Activation in the Prediction of Pediatric Venous Thromboembolic Outcomes: A Comparative Analysis with Respect to Adult Evidence. Hematology 2008:1, 236-244
CrossRef96
Guillermo Ruiz-Irastorza, Beverley J. Hunt, Munther A. Khamashta. (2007) A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis & Rheumatism 57:8, 1487-1495
CrossRef97
Guillermo Ruiz-Irastorza, Munther A. Khamashta. (2007) The treatment of antiphospholipid syndrome: A harmonic contrast. Best Practice & Research Clinical Rheumatology 21:6, 1079-1092
CrossRef98
D. A. Garcia, M. A. Khamashta, M. A. Crowther. (2007) How we diagnose and treat thrombotic manifestations of the antiphospholipid syndrome: a case-based review. Blood 110:9, 3122-3127
CrossRef99
Tunde Tarr, Gabriella Lakos, Harjit Pal Bhattoa, Pal Soltesz, Yehuda Shoenfeld, Gyula Szegedi, Emese Kiss. (2007) Clinical Thrombotic Manifestations in SLE Patients With and Without Antiphospholipid Antibodies: A 5-year Follow-up. Clinical Reviews in Allergy & Immunology 32:2, 131-137
CrossRef100
Robert Belv??s, Amparo Santamar??a, Joan Mart??-F??bregas, Rub??n G Leta, Dolores Cocho, Montserrat Borrell, Jordi Fontcuberta, Josep L Mart??-Vilalta. (2007) Patent foramen ovale and prothrombotic markers in young stroke patients. Blood Coagulation & Fibrinolysis 18:6, 537-542
CrossRef101
E. Muscal, R. L. Brey. (2007) Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine. International Journal of Clinical Practice 61:9, 1561-1568
CrossRef102
Wendy Lim, Mark A Crowther. (2007) Antiphospholipid antibiodies: a critical review of the literature. Current Opinion in Hematology 14:5, 494-499
CrossRef103
M. Galli, G. Borrelli, E. M. Jacobsen, R. M. Marfisi, G. Finazzi, R. Marchioli, F. Wisloff, S. Marziali, O. Morboeuf, T. Barbui. (2007) Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study. Blood 110:4, 1178-1183
CrossRef104
Angelo Ravelli, Alberto Martini. (2007) Antiphospholipid Syndrome in Pediatrics. Rheumatic Disease Clinics of North America 33:3, 499-523
CrossRef105
Kathleen M. O’Neil. (2007) Role of complement in antiphospholipid antibody-mediated thrombosis. Current Rheumatology Reports 9:3, 205-211
CrossRef106
Jose F. Roldan, Robin L. Brey. (2007) Neurologic manifestations of the antiphospholipid syndrome. Current Rheumatology Reports 9:2, 109-115
CrossRef107
John G. Hanly. (2007) New insights into central nervous system lupus: A clinical perspective. Current Rheumatology Reports 9:2, 116-124
CrossRef108
S. Schuchmann, T. Dörner. (2007) Antiphospholipid-Syndrom 2007. Zeitschrift für Rheumatologie 66:3, 198-205
CrossRef109
Sarah E. Wilson, Lorrie Costantini, Mark A. Crowther. (2007) Paper-based dosing algorithms for maintenance of warfarin anticoagulation. Journal of Thrombosis and Thrombolysis 23:3, 195-198
CrossRef110
Emma J MacDermott, Thomas JA Lehman. (2007) Antiphospholipid syndrome in children: review of pathogenesis, diagnosis and treatment. Future Rheumatology 2:2, 203-211
CrossRef111
J. O. J. Davies, B. J. Hunt. (2007) Myocardial infarction in young patients without coronary atherosclerosis: assume primary antiphospholipid syndrome until proved otherwise. International Journal of Clinical Practice 61:3, 379-384
CrossRef112
Ibrahim S. Abu Romeh, Adnan K. Chhatriwalla, Fernando A. Atik, Deepak L. Bhatt, Jose L. Navia. (2007) Myocardial Infarction Secondary to a Coronary Ostial Thrombus in Antiphospholipid Syndrome. The Annals of Thoracic Surgery 83:3, 1170-1171
CrossRef113
Michael J. Fischer, Joyce Rauch, Jerrold S. Levine. (2007) The Antiphospholipid Syndrome. Seminars in Nephrology 27:1, 35-46
CrossRef114
Jae Beom Lee, Yun Su Sim, Young Wook Noh, Hye Sung Park, Chung Hyun Tae, So Yeon Lim, Yoon Hee Jun, Yon Ju Ryu, Eun Mi Chun, Jin Hwa Lee, Jung Hyun Chang, Jin Wook Moon. (2007) A Case of Primary Antiphospholipid Syndrome with Pulmonary Thromboembolism. Tuberculosis and Respiratory Diseases 63:1, 72
CrossRef115
Yuuichirou SOGAWA, Yutaka SATO, Yuri KUDO, Takashi TAKEMAE, Akiko MIYAIRI, Yuki IZUMI. (2007) Rehabilitation of a Cerebral Infarction Patient with Antiphospholipid Syndrome. The Japanese Journal of Rehabilitation Medicine 44:2, 107-111
CrossRef116
Carl van Walraven, Peter C. Austin, Natalie Oake, Philip Wells, Muhammad Mamdani, Alan J. Forster. (2007) The effect of hospitalization on oral anticoagulation control: A population-based study. Thrombosis Research 119:6, 705-714
CrossRef117
Matthew T. Rondina, Robert C. Pendleton, Michelle Wheeler, George M. Rodgers. (2007) The treatment of venous thromboembolism in special populations. Thrombosis Research 119:4, 391-402
CrossRef118
Sanjiv J. Shah, Aubrey O. Ingraham, Sandra Y. Chung, Richard J. Haber. (2007) A distinguishing feature. Journal of Hospital Medicine 2:1, 39-45
CrossRef119
J. H. Rand. (2007) The Antiphospholipid Syndrome. Hematology 2007:1, 136-142
CrossRef120
Guillermo Ruiz-Irastorza, Munther A. Khamashta. (2007) Comments on the Editorial “Antiphospholypid Syndrome: New Clinical and Therapeutic Perspectives”. Reumatolog ía Cl ínica (English Edition) 3:2, 90
CrossRef121
Samuel Z. Goldhaber. 2007. Deep Vein Thrombosis and Pulmonary Embolism. , 245-256.
CrossRef122
Jacob H. Rand, Miles B. Levin, Barbara M. Alving. 2007. The Antiphospholipid Syndrome: Clinical Presentation, Diagnosis, and Patient Management. , 319-338.
CrossRef123
Jody L. Kujovich, Barbara M. Alving. 2007. Management of Thrombophilia and Antiphospholipid Syndrome During Pregnancy. , 593-609.
CrossRef124
Christine L. Hann, Michael B. Streiff. 2007. Vena Caval Filters. , 531-552.
CrossRef125
D. WARE BRANCH, ALEXANDRA GROSVENOR Eller. (2006) Antiphospholipid Syndrome and Thrombosis. Clinical Obstetrics and Gynecology 49:4, 861-874
CrossRef126
Alessandra Bruns, Olivier Meyer. (2006) Neuropsychiatric manifestations of systemic lupus erythematosus. Joint Bone Spine 73:6, 639-645
CrossRef127
Silvia S Pierangeli, Pojen P Chen, Emilio B González. (2006) Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Current Opinion in Internal Medicine 5:6, 584-593
CrossRef128
Shawnna L Patterson, Marian P LaMonte, Jamal A Mikdashi, Stuart T Haines, Marcie J Hursting. (2006) Anticoagulation Strategies for Treatment of Ischemic Stroke and Antiphospholipid Syndrome: Case Report and Review of the Literature. Pharmacotherapy 26:10, 1518-1525
CrossRef129
F DENTALI. (2006) Acquired Thrombophilia during Pregnancy. Obstetrics and Gynecology Clinics of North America 33:3, 375-388
CrossRef130
Doruk Erkan, Michael D Lockshin. (2006) Antiphospholipid syndrome. Current Opinion in Internal Medicine 5:4, 378-384
CrossRef131
Michelle Petri, Umair Qazi. (2006) Management of Antiphospholipid Syndrome in Pregnancy. Rheumatic Disease Clinics of North America 32:3, 591-607
CrossRef132
Beverley Robertson, Mike Greaves. (2006) Antiphospholipid syndrome: An evolving story. Blood Reviews 20:4, 201-212
CrossRef133
Guillermo Ruiz-Irastorza, Munther A Khamashta. (2006) Antiphospholipid syndrome: treatment controversies. Future Rheumatology 1:3, 345-353
CrossRef134
Paul DeMarco, Inderprit Singh, Arthur Weinstein. (2006) Management of the antiphospholipid syndrome. Current Rheumatology Reports 8:2, 114-120
CrossRef135
Stephan Moll. (2006) Thrombophilias—Practical Implications and Testing Caveats. Journal of Thrombosis and Thrombolysis 21:1, 7-15
CrossRef136
T. P. Baglin, D. M. Keeling, H. G. Watson, . (2006) Guidelines on oral anticoagulation (warfarin): third edition - 2005 update. British Journal of Haematology 132:3, 277-285
CrossRef137
Thomas L. Ortel. (2006) The Antiphospholipid Syndrome: What are We Really Measuring? How do We Measure it? And How do We Treat it?. Journal of Thrombosis and Thrombolysis 21:1, 79-83
CrossRef138
Doruk Erkan, Michael D. Lockshin. (2006) New Treatments for Antiphospholipid Syndrome. Rheumatic Disease Clinics of North America 32:1, 129-148
CrossRef139
Johann Motsch, Andreas Walther, Matthias Bock, Bernd W. B??ttiger. (2006) Update in the prevention and treatment of deep vein thrombosis and pulmonary embolism. Current Opinion in Anaesthesiology 19:1, 52-58
CrossRef140
Alex C. Spyropoulos. (2006) Managing Oral Anticoagulation Requires Expert Experience and Clinical Evidence. Journal of Thrombosis and Thrombolysis 21:1, 91-94
CrossRef141
Robin L. Brey. (2005) Antiphospholipid Antibodies in Young Adults with Stroke. Journal of Thrombosis and Thrombolysis 20:2, 105-112
CrossRef142
John G. Hanly, Melanie J. Harrison. (2005) Management of neuropsychiatric lupus. Best Practice & Research Clinical Rheumatology 19:5, 799-821
CrossRef143
N. S. KEY. (2005) More on: intensity of warfarin anticoagulation in APS. Journal of Thrombosis and Haemostasis 3:10, 2368-2369
CrossRef144
Heng Joo Ng, Mark A Crowther. (2005) Anticoagulation therapy in the antiphospholipid syndrome: recent advances. Current Opinion in Pulmonary Medicine 11:5, 368-372
CrossRef145
F. DENTALI, E. MANFREDI, M. CROWTHER, W. AGENO. (2005) Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. Journal of Thrombosis and Haemostasis 3:9, 2121-2123
CrossRef146
Yasmin Wadia, Perumal Thiagarajan, Reynolds Delgado, Paul Allison, Kimberly Robertson, O.H. Frazier. (2005) Antiphospholipid Syndrome With Anti-Prothrombin Autoantibodies in a Patient With an Axial-Flow Left Ventricular Assist Device. The Journal of Heart and Lung Transplantation 24:8, 1133-1136
CrossRef147
K. Wahbi, E. Salengro, L. Galicier, L. Guillevin, C. Spaulding, S Weber, C. Meune. (2005) Survenue d'un infarctus du myocarde après arrêt de l'aspirine et des corticoïdes oraux chez une patiente présentant un syndrome des antiphospholipides. Annales de Cardiologie et d'Angéiologie 54:4, 212-215
CrossRef148
H. R. BULLER, M. SOHNE, S. MIDDELDORP. (2005) Treatment of venous thromboembolism. Journal of Thrombosis and Haemostasis 3:8, 1554-1560
CrossRef149
Lisa R. Sammaritano. (2005) Antiphospholipid Syndrome: Review. Southern Medical Journal 98:6, 617-625
CrossRef150
SILVIA S. PIERANGELI, MARIANO VEGA-OSTERTAG, XIAOWEI LIU, GUILLERMINA GIRARDI. (2005) Complement Activation: A Novel Pathogenic Mechanism in the Antiphospholipid Syndrome. Annals of the New York Academy of Sciences 1051:1, 413-420
CrossRef151
Mariano Vega-Ostertag, Katherine Casper, Robert Swerlick, Dardo Ferrara, E. Nigel Harris, Silvia S. Pierangeli. (2005) Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis & Rheumatism 52:5, 1545-1554
CrossRef152
M. A. KHAMASHTA, B. J. HUNT. (2005) Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. Journal of Thrombosis and Haemostasis 3:5, 844-845
CrossRef153
D. R. ANDERSON. (2005) Oral anticoagulation for the antiphospholipid antibody syndrome: can we now say less is more?. Journal of Thrombosis and Haemostasis 3:5, 846-847
CrossRef154
G. FINAZZI, R. MARCHIOLI, V. BRANCACCIO, P. SCHINCO, F. WISLOFF, J. MUSIAL, F. BAUDO, M. BERRETTINI, S. Testa, A. D'ANGELO, G. TOGNONI, T. BARBUI. (2005) A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)1. Journal of Thrombosis and Haemostasis 3:5, 848-853
CrossRef155
F. R. RICKLES, V. J. MARDER. (2005) Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No. Journal of Thrombosis and Haemostasis 3:5, 842-843
CrossRef156
M.-F. SCULLY. (2005) Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? Yes. Journal of Thrombosis and Haemostasis 3:5, 840-841
CrossRef157
John G. Hanly. (2005) Neuropsychiatric Lupus. Rheumatic Disease Clinics of North America 31:2, 273-298
CrossRef158
C LECROY, M PATTERSON, S TAYLOR, A WESTFALL, W JORDANJR. (2005) Effect of Warfarin Anticoagulation on Below-Knee Polytetrafluoroethylene Graft Patency. Annals of Vascular Surgery 19:2, 192-198
CrossRef159
R. Weber, E. Busch. (2005) Thrombophilien bei Patienten mit isch
CrossRef160
Graham F. Pineo, Russell D. Hull. (2005) Vitamin K Antagonists and Direct Thrombin Inhibitors: Present and Future. Hematology/Oncology Clinics of North America 19:1, 69-85
CrossRef161
Mark A. Crowther, Finn Wisloff. (2005) Evidence based treatment of the antiphospholipid syndrome. Thrombosis Research 115:1-2, 3-8
CrossRef162
Zhong-Xuan Ye, Wen-Chung Yu, Chun-Mei Hsueh, Hsin-Bang Leu, Jaw-Wen Chen, Shing-Jong Lin. (2005) Antiphospholipid Syndrome Presenting as Intracardiac Thrombus With Pulmonary Embolism. Circulation Journal 69:10, 1290-1292
CrossRef163
Jeanne M. LaBerge, Robert K. Kerlan, Darren B. Schneider, Roy L. Gordon. (2005) Extensive Peripheral, Iliofemoral, and Caval Thrombosis in a 16-Year-Old Girl. Journal of Vascular and Interventional Radiology 16:1, 133-137
CrossRef164
Jennifer M. Grossman. (2004) Primary versus secondary antiphospholipid syndrome: Is this lupus or not?. Current Rheumatology Reports 6:6, 445-450
CrossRef165
Christopher Wu, Kenneth Kalunian. (2004) Treatment of the antiphospholipid antibody syndrome. Current Rheumatology Reports 6:6, 463-468
CrossRef166
R. M. Bauersachs. (2004) Therapie der Beinvenenthrombose. Der Internist 45:12, 1345-1355
CrossRef167
D. E. Ferrara, R. Swerlick, K. Casper, P.L. Meroni, M.E. Vega-Ostertag, E.N. Harris, S. S. Pierangeli. (2004) Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells. Journal of Thrombosis and Haemostasis 2:9, 1558-1563
CrossRef168
Terry K. Rosborough, Michele F. Shepherd. (2004) Unreliability of International Normalized Ratio for Monitoring Warfarin Therapy in Patients with Lupus Anticoagulant. Pharmacotherapy 24:7, 838-842
CrossRef169
P. M. Ridker. (2004) Long-term low-dose warfarin use is effective in the prevention of recurrent venous thromboembolism: yes. Journal of Thrombosis and Haemostasis 2:7, 1034-1037
CrossRef170
Jim Thom, Leesa Ivey, Grace Gilmore, John W Eikelboom. (2004) Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant. Blood Coagulation & Fibrinolysis 15:4, 353-357
CrossRef171
J WARREN, R SILVER. (2004) Autoimmune disease in pregnancy: systemic lupus erythematosus and antiphospholipid syndrome. Obstetrics and Gynecology Clinics of North America 31:2, 345-372
CrossRef172
Arina J ten Cate-Hoek, Martin H Prins. (2004) Appropriate level and length of postthrombotic warfarin treatment: an evaluation of recent developments. Current Opinion in Hematology 11:3, 182-186
CrossRef173
Stanley Tuhrim. (2004) Antiphospholipid antibodies and stroke. Current Cardiology Reports 6:2, 130-134
CrossRef174
Richard L Mueller. (2004) First-generation agents: aspirin, heparin and coumarins. Best Practice & Research Clinical Haematology 17:1, 23-53
CrossRef175
Keith A Cockerill, G Michael Iverson, David S Jones, Matthew D Linnik. (2004) Therapeutic Potential of Toleragens in the Management of Antiphospholipid Syndrome. BioDrugs 18:5, 297-305
CrossRef176
Doruk Erkan, Michael D. Lockshin. (2004) How much warfarin is enough in APS related thrombosis?. Thrombosis Research 114:5-6, 435-442
CrossRef177
Mark A. Crowther. (2004) Anticoagulant therapy for the thrombotic complications of the antiphospholipid antibody syndrome. Thrombosis Research 114:5-6, 443-446
CrossRef178
Robin L. Brey. (2004) Management of the neurological manifestations of APS—what do the trials tell us?. Thrombosis Research 114:5-6, 489-499
CrossRef179
Paul A. Gatenby. (2004) Controversies in the antiphospholipid syndrome and stroke. Thrombosis Research 114:5-6, 483-488
CrossRef180
Ronald H.W.M. Derksen, Philip G. de Groot. (2004) Tests for lupus anticoagulant revisited. Thrombosis Research 114:5-6, 521-526
CrossRef181
Silvia S. Pierangeli, Mariano Vega-Ostertag, E. Nigel Harris. (2004) Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. Thrombosis Research 114:5-6, 467-476
CrossRef182
(2003) Warfarin Prophylaxis in the Antiphospholipid Antibody Syndrome. New England Journal of Medicine 349:26, 2568-2570
Full Text183
Lockshin, Michael D., Erkan, Doruk, . (2003) Treatment of the Antiphospholipid Syndrome. New England Journal of Medicine 349:12, 1177-1179
Full Text
- Letters
